ROSLIN, SCOTLAND — A biotechnology plant at Howkley Moss will house a new $61 million (GBP 42 million) manufacturing facility that will produce treatments of cystic fibrosis and other lung disorders.

The facility, which is expected to create 900 jobs and attract nearly $102 million (GBP $70 million), will work primarily on a treatment called recombinant human alpha-1-antitrypsin (rAAT). The treatment, which was developed by PPL Therapeutics, is a human protein from the milk of genetically modified sheep.

Thermal Transfer, a provider of mechanical and engineering building services, turnkey cleanroom contracts, laboratories and cleanrooms will serve as designers and contractors of the new facility.

One official called the facility “the missing link in the chain for Start-up biotechnology firms” in Scotland.

Work on the project is expected to begin in April.